In combined drug-target Mendelian randomization and colocalization analyses of 78 473 cases and 107 143 controls, genetically proxied ANGPTL4 inhibition was associated with a reduced risk of colorectal cancer. Here, ANGPTL4 is linked to colorectal cancer.